glp·helper
glphelper.com/mounjaro/california/santa-monica
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Santa Monica, CA

Verified Mounjaro providers in Santa Monica, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
37
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
38 of 38 shown

Find a Mounjaro provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /mounjaro/california/{city}
§ 03Getting Mounjaro in California
38 providers · 62 metros

How a prescription works in California.

You don’t have to leave California to start. Because tirzepatide isn't a controlled substance, a California-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 38 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in California
Mounjaro (tirzepatide) is a GLP-1, not a controlled substance, so a California-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
CA-licensed clinicians
Any physician, nurse practitioner, or PA licensed in California can prescribe Mounjaro. The 38 providers below are checked against the NPI registry and the California board.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Santa Monica

Santa Monica, California has a population of 93,076 people. The adult obesity rate in Santa Monica is an age-adjusted estimate of 22.7%, 6.4 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 7.7% of adults in Santa Monica. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 15.6% of adults in Santa Monica.

of Santa Monica adults have obesity
22.7%
diagnosed diabetes
7.7%
no regular physical activity
15.6%

Age-adjusted estimates for Santa Monica, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossmale-specific GLP-1 side effects
§ 05Support around Mounjaro in Santa Monica
6 fitness clubs

The prescription is one part. Here is the rest, in Santa Monica.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Santa Monica, CA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Circuit Works
FITNESS
5.0 on Google · 485 reviews
1837 Lincoln Blvd
Website
JOHN REED Fitness
FITNESS
3.8 on Google · 200 reviews
1202 3rd Street Promenade
Website
Training Mate Santa Monica
FITNESS
4.9 on Google · 101 reviews
1454 Lincoln Blvd
Website
My Gym Santa Monica
FITNESS
4.9 on Google · 13 reviews
2827 Main St
Website
Santa Monica Family YMCA
FITNESS
3.9 on Google · 256 reviews
1332 6th St
Website
TRIFIT LA
GYM
4.6 on Google · 190 reviews
2425 Colorado Ave Ste B100
Website

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Lotta Andonian, MS
NUTRITIONIST
Nutritionist
1902 Westwood Blvd Ste 201
Call 347-326-1726NPI 1952140717
Lolita Carrico, CN
NUTRITIONIST
Nutritionist · Education
2219 Main St Unit 515
Call 323-685-6663NPI 1780378786
Murray Clarke, L.Ac
NUTRITIONIST
Nutritionist
900 Wilshire Blvd
Call 310-395-8363NPI 1790078616
Julie Delabarre, CN
NUTRITIONIST
Nutritionist · Education
1755 Ocean Ave Apt 306
Call 818-687-8296NPI 1982524104
Nicole Kuhl Visnic, CCN
NUTRITIONIST
Nutritionist
2811 Wilshire Blvd Ste 610
Call 310-453-2335NPI 1588072565
Maria Locsin, L. Ac
NUTRITIONIST
Nutritionist
2001 S Barrington Ave
Call 310-396-4195NPI 1568584027
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in California

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]